Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30322% above fair value
$29.04−0.44 (-1.49%)
Close on Nov 13, 2026Market cap $4.63BP/E –Yield –
Adaptive Biotechnologies enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Adaptive Biotechnologies's enterprise value was $4.43B on Nov 11, 2026, against $2.92B a year earlier. Over the last 5 years it ranged from $164.25M to $4.43B, with a median of $889.92M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $4.43B | +84.7% |
| 2025 | Dec 31, 2025 | $2.40B | +209.7% |
| 2024 | Dec 31, 2024 | $773.80M | +65.3% |
| 2023 | Dec 29, 2023 | $468.08M | -19.9% |
| 2022 | Dec 30, 2022 | $584.32M | -83.5% |
| 2021 | Dec 31, 2021 | $3.54B | -51.0% |
| 2020 | Dec 31, 2020 | $7.23B | +129.8% |
| 2019 | Dec 31, 2019 | $3.15B | – |
See a number that looks wrong?